Effect of sodium zirconium cyclosilicate (SZC) on rapid correction of hyperkalemia before kidney transplantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072940

Enrollment

Unknown

Registered

2023-06-28

Start date

2023-06-28

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperkalemia in chronic kidney disease stage 5

Interventions

10g group (10g sodium zirconium cyclosilicate):None

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Voluntary signing of informed consent form; 2.Male or female, aged 18 to 65 years old; 3.Diagnosed as hyperkalemia according to the diagnostic criteria of "expert recommendations for the risk assessment and management of hyperkalemia in chronic kidney disease (2020)", and the initial venous potassium concentration was 5.0 ~ 7.0mmol/l; 4.Patients taking 10g SZC for potassium reduction according to the judgment of the attending physician.

Exclusion criteria

Exclusion criteria: 1.Combined with other potassium reduction measures; 2.Pregnant woman or suckling period woman; 3.Patients judged by the investigator as unsuitable for participation in this trial.

Design outcomes

Primary

Measure	Time frame
Serum potassium;	—

Countries

China

Contacts

Public ContactMiao Yun

Department of Organ Transplantation,Nanfang Hospital,Southern Medical University

miaoyunecho@126.com+86 139 2602 8823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026